Wave's New Weight-Loss Drug Outperforms Semaglutide in Fat Reduction

Wave Life Sciences has released promising mid-stage trial results for its experimental weight-loss drug, WVE-007. Over three months, the treatment cut total body fat by 4.5%, outperforming early-stage data from existing GLP-1 medications like semaglutide. Investors reacted quickly, pushing the company's share price up by 15% in after-hours trading on 4 February 2026.

The trial showed WVE-007 reduced body fat more effectively than semaglutide at a similar development stage. Unlike some weight-loss drugs, it did not cause muscle loss, according to CEO Paul Bolno. He also highlighted its strong safety record and tolerability in participants.

Wave plans to directly compare WVE-007's performance with FDA-approved GLP-1 treatments like semaglutide in future studies. The company reported no major side effects, reinforcing confidence in the drug's profile.

Following the announcement, Wave's stock climbed from $42.50 to $48.90 in extended trading. The jump reflects growing optimism about the drug's potential in the competitive obesity treatment market.

WVE-007's early success positions it as a strong contender against established weight-loss medications like semaglutide. The next phase will test it against approved GLP-1 drugs, with safety and fat-reduction benefits already noted. If results hold, it could offer a new option for patients seeking effective, muscle-sparing fat loss.